The LA-headquartered company, which once had 500 stores, is working with restructuring adviser BRG to address its ongoing ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

Josh Dury shares his globe-trotting experiences, revealing insights into our universe and the importance of protecting the ...

AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

U.S. stocks DJIA SPX COMP have opened lower, with Treasury yields BX:TMUBMUSD10Y BX:TMUBMUSD02Y slipping. Gold (GC00) hit a fresh record, while the dollar DXY is lower.

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...